ConductScience.org, home

Comparison · NCT00976963-sae

TMP/SMX vs Fosfomycin: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. TMP/SMX vs Fosfomycin: serious adverse events. Trial comparisons, record NCT00976963-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00976963-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 100.000000000000000001730.025wilson
Risk in group 200.000000000000000001730.025wilson
Risk difference, group 1 minus group 20-0.0250.025newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1TMP/SMXSulfamethoxazole-Trimethoprim 800-160 MG Oral Tab; 160/800mg BID x 3 days~TMP/SMX : Take one twice daily for 3 days for urinary tract infection0150EG000
Group 2Fosfomycin3g sachet single dose~Fosfomycin: Mix sachet with 1/2 glass cold water and stir. Drink immediately0150EG001

Harm

What it counts
Total, serious adverse events
Time frame
30 days

Source ClinicalTrials.gov

Trial

Title
Single Dose Monurol for Treatment of Acute Cystitis
NCT number
NCT00976963
Phases
NA
Conditions
Urinary Tract Infection
Interventions
TMP/SMX, Fosfomycin
Lead sponsor
University of Washington
Results first posted
2023-06-05

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00976963-sae